About The Study: Mazdutide, a once-weekly glucagon and glucagon-like peptide-1 (GLP-1) receptor dual agonist, provided clinically meaningful weight reduction in Chinese adults with moderate to severe obesity compared with placebo, but participants receiving the drug experienced gastrointestinal adverse reactions compared with those receiving placebo.
Corresponding Authors: To contact the corresponding authors, email Linong Ji, MD, ( jiln@bjmu.edu.cn ) and Lei Qian, MD, PhD, ( cnradium@126.com ).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2026.8142)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the 2026 American Diabetes Association’s Scientific Sessions.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.8142?guestAccessKey=9423bd8d-ce4d-4436-a71b-b69ef4a18126&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060726
JAMA